The use of interferon-alpha 5 in the treatment of viral liver disease

 

The invention relates to medicine and can be used for the treatment of liver diseases of viral origin. The invention is the use of interferon-alpha 5 or gene sequence that encodes interferon-alpha 5, as a means to treat liver disease caused by hepatitis C. the Proposed method can improve the effectiveness of the treatment. 8 C.p. f-crystals, 1 tab., 3 Il.

Description text in facsimile form (see graphic part). Those

Claims

1. The use of interferon-alpha 5 or gene sequence that encodes interferon-alpha 5, as a means to treat liver disease caused by hepatitis C.

2. Application under item 1, where liver disease is chronic hepatitis C.

3. Application under item 1, where liver disease is cirrhosis of viral origin.

4. Application under item 1, where liver disease is a malignant hepatoma.

5. The use according to any one of paragraphs.1-4, where the interferon-alpha 5 is a recombinant protein interferon-alpha 5, obtained by cloning in a suitable host expressing vector, the content is I cloning is a eukaryotic organism, preferably Esherichia coli.

7. Application under item 5, in which a host for cloning is a prokaryotic organism, preferably Solanum tuberosum.

8. Use PP.1-7, where the interferon-alpha 5 or gene sequence encoding interferon-alpha 5, may be included in any food product.

9. Use PP.1-4, where a gene sequence encoding interferon - alpha 5, is applied using somatic gene therapy.

 

Same patents:

The invention relates to medicine and for the treatment and prevention of cholelithiasis
The invention relates to medicine, infectious diseases and can be used for the treatment of acute viral hepatitis In

The invention relates to medicine, namely to Hepatology and immunology, and the development of a method for correcting biochemical and immunological changes in conditions of experimental acute toxic Hepatology, accompanied by an increase in immune responsiveness

The invention relates to medicine, in particular to surgery, and can be used for the treatment of toxic hepatitis and cirrhosis
The invention relates to medicine, in particular to a gastroenterologist, and can be used for pathogenetic treatment of chronic liver diseases

The invention relates to pharmaceutical industry

The invention relates to medicine and can be used for the treatment of dysfunctions of the hepatobiliary system of different origin

The invention relates to medicine, namely to pulmonology and concerns immunocorrective treatment of patients with bronchopulmonary pathology

Antiviral agent // 2204410
The invention relates to medicine and refers to the local application of the effect, for example, in dentistry, surgery, otolaryngology, gynecology for the treatment of herpes and other infections caused by viruses, bacteria, namely antiviral agent containing human leukocyte interferon and the substrate in the form of plate, as a basis containing collagen, the activity of interferon in the plate is not less than 3000 ME
The invention relates to the field of medicine and relates to means broad-spectrum interferon-based
The invention relates to medicine, namely to the treatment of infectious diseases, and for the treatment of recurrent herpes
The invention relates to the field of medicine
The invention relates to medicine, namely to Pediatrics, and can be used for the treatment of respiratory viral infections in children in the first year of life

The invention relates to medicine, therapy, can be used for the treatment of chronic viral hepatitis

The invention relates to medicine, namely to Virology, immunology, pharmacology, concerns the creation tools and development methods for increasing resistance to infection
The invention relates to medicine, in particular to neonatologie, and is intended for the treatment of respiratory distress syndrome in newborns

The invention relates to medicine, refers to a medicinal product in the form of a solution and can be used in ophthalmology, otorinolaryngology, Pediatrics and gynecology

FIELD: medicine, anesthesiology-resuscitation, infectology, detoxication.

SUBSTANCE: the innovation suggested interrupts infectious-toxic shock, moreover, after that it is necessary to prescribe peroral intake of Reaferon-EC-Lipint at the dosage of 10000 - 15000 U/kg. Then one should sample patient's blood to obtain leukocytes to be washed and diluted in 0.9%-NaCl solution, activated due to incubation with immunophan and intravenously injected for a patient. Then comes peroral intake of Reaferon-EC-Lipint at the dosage of 10000 - 15000 U/kg once daily for 5 d. The innovation enables to decrease the number of complications and lethality due to decreasing immunodeficiency.

EFFECT: higher efficiency of therapy.

3 ex, 1 tbl

Up!